13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

Key Takeaways Explain This Topic AI

The 2014 ACC/AHA perioperative cardiac evaluation algorithm prioritizes surgical urgency (emergency surgery proceeds directly to OR), active unstable coronary syndromes (postpone elective surgery), and functional capacity: patients achieving ≥4 METs (e.g., climbing a flight of stairs) can proceed to elevated-risk surgery without additional cardiac testing.

The Revised Cardiac Risk Index (RCRI / Lee Index) incorporates 6 independent clinical predictors: high-risk surgery (intraperitoneal, intrathoracic, vascular), ischemic heart disease, congestive heart failure, cerebrovascular disease, insulin-treated diabetes, and preoperative serum creatinine >2.0 mg/dL; a score ≥2 denotes elevated risk (6.6% to ≥11% MACE).

AAFP and Choosing Wisely guidelines advise against routine preoperative ECG, CBC, BMP, coagulation profiles, or chest radiography in asymptomatic patients undergoing low-risk or minor surgery, reserving tests exclusively for specific comorbidity-driven indications.

Perioperative pharmacotherapy mandates continuing chronic beta-blockers and statins, withholding ACE inhibitors and ARBs for 24 hours preoperatively to prevent refractory vasoplegic hypotension, and holding SGLT2 inhibitors for 3–4 days prior to surgery to prevent life-threatening euglycemic diabetic ketoacidosis.

The AHA 14-element athletic PPE screening targets sudden cardiac death risk; dynamic auscultation is vital: a systolic murmur that increases in intensity with the Valsalva maneuver or standing indicates hypertrophic cardiomyopathy (HCM), whereas an innocent flow murmur diminishes; confirmed concussions mandate immediate removal from play and a 6-stage graduated return-to-play protocol.

Last updated: September 2026

Preoperative Cardiovascular Risk Assessment: ACC/AHA Framework

The primary purpose of the preoperative medical evaluation is not to "clear" a patient for surgery, but to provide an objective, evidence-based assessment of perioperative risk, identify unrecognized medical comorbidities, and optimize clinical management. Cardiovascular complications—including myocardial infarction, acute decompensated heart failure, and malignant arrhythmias—represent the leading causes of perioperative morbidity and mortality in noncardiac surgery.

The 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management outlines a structured, stepwise decision-making algorithm:

Stepwise Algorithmic Approach

Step 1: Surgical Urgency

Emergency Surgery (life or limb threatened without intervention within < 6 <6 < 6 hours): Proceed directly to the operating room. There is no time for noninvasive cardiac testing. Provide clinical surveillance, perioperative hemodynamic monitoring, and postoperative cardiac enzyme surveillance.

Urgent Surgery (within 6 to 24 hours): Proceed with focused medical optimization; testing is rarely indicated.

Elective Surgery : Proceed to Step 2.

Step 2: Identify Active / Unstable Cardiac Conditions Elective noncardiac surgery must be postponed for diagnostic evaluation and medical stabilization if any of the following active conditions are identified:

Unstable Coronary Syndromes : Unstable or severe angina (Canadian Cardiovascular Society [CCS] Class III or IV), recent acute myocardial infarction ( < 30 <30 < 30 days) with residual ischemia.

Decompensated Heart Failure : New-onset heart failure, worsening dyspnea at rest (NYHA Class IV), physical exam signs of volume overload (elevated jugular venous distention, S3 gallop, bibasilar pulmonary crackles, progressive peripheral edema).

Significant Symptomatic Arrhythmias : High-grade atrioventricular block (Mobitz Type II or third-degree AV block), symptomatic ventricular tachyarrhythmias, uncontrolled supraventricular arrhythmias (e.g., atrial fibrillation with rapid ventricular response > 110 >110 > 110 bpm).

Severe Symptomatic Valvular Heart Disease : Specifically severe symptomatic aortic stenosis (aortic valve area < 1.0 cm 2 <1.0\text{ cm}^2 < 1.0 cm 2 , mean transvalvular gradient > 40 mm Hg >40\text{ mm Hg} > 40 mm Hg , or jet velocity > 4.0 m/s >4.0\text{ m/s} > 4.0 m/s with angina, syncope, or heart failure symptoms). Severe aortic stenosis carries a 10% to 30% risk of perioperative cardiac death or infarction and mandates surgical or transcatheter aortic valve replacement prior to elective noncardiac procedures.

Step 3: Surgical Procedural Risk Stratification

Low-Risk Surgery ( < 1 % <1\% < 1% Combined 30-Day Risk of MACE [Cardiac Death or Nonfatal MI]) : Cataract extraction, superficial dermatologic surgery, breast biopsy/lumpectomy, minor plastic surgery, ambulatory orthopedic procedures, diagnostic endoscopy. Management: Proceed directly to surgery without additional cardiac testing , regardless of underlying patient comorbidities.

Elevated-Risk Surgery ( ≥ 1 % \ge 1\% ≥ 1% Combined 30-Day Risk of MACE) : Intraperitoneal operations (colectomy, gastrectomy, exploratory laparotomy), intrathoracic procedures (pneumonectomy, lobectomy), vascular procedures (open abdominal aortic aneurysm repair, suprainguinal bypass), major orthopedic surgery (total hip or knee arthroplasty), head and neck oncologic resections. Management: Proceed to Step 4.

Step 4: Functional Capacity Assessment in Metabolic Equivalents (METs) Functional capacity is quantified using Metabolic Equivalents of Task (METs) , where 1 MET represents the resting metabolic rate (oxygen uptake of approximately 3.5 mL O₂/kg/min):

Functional Threshold (4 METs) : An individual has preserved functional capacity ( ≥ 4 METs \ge 4\text{ METs} ≥ 4 METs ) if they can climb a flight of stairs without stopping, walk up a steep hill, walk on level ground at 4 mph (6.4 km/h), carry heavy groceries upstairs, perform heavy household chores (e.g., scrubbing floors, vacuuming, moving furniture), or participate in moderate recreational activities (e.g., golfing without a cart, doubles tennis, dancing).

Clinical Rule : If a patient scheduled for elevated-risk surgery has functional capacity ≥ 4 METs \ge 4\text{ METs} ≥ 4 METs without cardiac symptoms , they may proceed to surgery WITHOUT further cardiac testing , even in the presence of established cardiovascular comorbidities.

If functional capacity is poor ( < 4 METs <4\text{ METs} < 4 METs ) or unknown (e.g., sedentary, wheelchair-bound, severe joint pain limiting mobility), proceed to Step 5.

Step 5: Revised Cardiac Risk Index (RCRI / Lee Index) For patients with poor or unknown functional capacity undergoing elevated-risk surgery, assess the Revised Cardiac Risk Index (RCRI) .

The Revised Cardiac Risk Index (RCRI / Lee Index)

The RCRI incorporates six independent clinical predictors of major adverse cardiac events (MACE) , assigning 1 point to each predictor present:

High-Risk Surgical Procedure : Intraperitoneal, intrathoracic, or suprainguinal vascular surgery.

History of Ischemic Heart Disease : History of myocardial infarction, positive prior exercise stress test, current angina, nitrate use, or ECG demonstrating pathological Q waves.

History of Congestive Heart Failure : Current heart failure, history of pulmonary edema, paroxysmal nocturnal dyspnea, S3 gallop, bibasilar rales, or documented left ventricular ejection fraction (LVEF) < 40 % <40\% < 40% .

History of Cerebrovascular Disease : Prior transient ischemic attack (TIA) or stroke (ischemic or hemorrhagic).

Preoperative Insulin-Treated Diabetes Mellitus : Patient requires chronic insulin therapy. ( Exam Pearl : Oral antidiabetic therapy alone does NOT score a point on the RCRI).

Preoperative Renal Insufficiency : Preoperative baseline serum creatinine > 2.0 mg/dL >2.0\text{ mg/dL} > 2.0 mg/dL ( > 177 μ mol/L >177\;\mu\text{mol/L} > 177 μ mol/L ).

RCRI Scoring & 30-Day MACE Stratification

RCRI Class Number of Predictors Estimated 30-Day MACE Risk Clinical Action in Poor Functional Capacity ( < 4 <4 < 4 METs)

• Class I 0 Predictors 0.4% (Low Risk) Proceed directly to surgery without cardiac testing
• Class II 1 Predictor 0.9% (Low Risk) Proceed directly to surgery without cardiac testing

Class III 2 Predictors 6.6% (Elevated Risk) Pharmacologic stress testing indicated ONLY IF results will alter management

Class IV ≥ 3 \ge 3 ≥ 3 Predictors ≥ 11.0 % \ge 11.0\% ≥ 11.0% (Elevated Risk) Pharmacologic stress testing indicated ONLY IF results will alter management

THE DECISION-MAKING PEARL : Even in RCRI Class III or IV with poor functional capacity, pharmacologic cardiac stress testing (dobutamine stress echocardiography or pharmacologic myocardial perfusion scintigraphy) is indicated ONLY IF the test results will alter clinical management (e.g., the patient is a suitable candidate for, and would agree to undergo, coronary artery revascularization or delay of surgery). If revascularization would not be pursued regardless of findings, or if surgery cannot be delayed, stress testing produces unnecessary delays and false positives; the patient should proceed to surgery with medical optimization and perioperative hemodynamic monitoring.

High-Value Diagnostic Stewardship (Choosing Wisely Guidelines)

Both the American Academy of Family Physicians (AAFP) and the American College of Physicians (ACP), through the Choosing Wisely campaign, emphasize that routine preoperative "battery" testing in asymptomatic patients yields zero clinical benefit while generating false positives, unneeded subspecialty consultations, cancelled surgeries, and increased costs.

High-Yield Testing Recommendations

Routine Preoperative 12-Lead Electrocardiogram (ECG) :

Choosing Wisely Rule : Do NOT obtain routine baseline ECGs in asymptomatic patients undergoing low-risk surgical procedures.

Appropriate Indications : ECG is indicated for patients undergoing elevated-risk surgery who have known cardiovascular disease, significant arrhythmias, peripheral artery disease, severe systemic comorbidity, or ≥ 1 \ge 1 ≥ 1 RCRI predictor.

Routine Complete Blood Count (CBC) :

Choosing Wisely Rule : Do NOT order routine baseline CBC in healthy, asymptomatic patients.

Appropriate Indications : Anticipated substantial procedural blood loss ( > 500 mL >500\text{ mL} > 500 mL ), patients with clinical signs or symptoms of anemia, suspected myelosuppression, chronic liver or renal disease, or patients receiving active antineoplastic chemotherapy.

Routine Serum Chemistries & Renal Function (BMP) :

Choosing Wisely Rule : Do NOT order routine electrolytes or creatinine in healthy patients.

Appropriate Indications : Known chronic kidney disease, diabetes mellitus, congestive heart failure, liver disease, or patients taking medications that alter renal function or electrolytes (e.g., ACE inhibitors, ARBs, diuretics, digoxin, lithium).

Routine Coagulation Studies (PT/INR and aPTT) :

Choosing Wisely Rule : Do NOT order routine coagulation screening prior to surgery.

Evidence : Normal coagulation tests do NOT predict intraoperative or postoperative bleeding in patients with an unremarkable bleeding history. Testing is indicated ONLY if the patient has a personal or family history of abnormal bleeding/diathesis, end-stage liver disease, severe malabsorption/malnutrition, or is receiving active anticoagulant pharmacotherapy.

Routine Preoperative Chest Radiography (CXR) :

Choosing Wisely Rule : Do NOT obtain routine screening chest radiographs.

Appropriate Indications : New or unstable cardiopulmonary symptoms (acute dyspnea, new cough, wheezing), suspected pneumonia, or decompensated chronic pulmonary disease.

Perioperative Medication Management

Managing chronic medications perioperatively requires balancing the risks of surgical bleeding and drug interactions against the risks of chronic disease destabilization:

Master Perioperative Medication Protocol

Medication / Drug Class Surgical Timing Action Clinical Rationale & High-Yield Exam Pearls

Beta-Blockers (e.g., metoprolol, atenolol) CONTINUE through morning of surgery with a sip of water Abrupt withdrawal causes rebound sympathetic surge, tachycardia, hypertension, and ischemia. CRITICAL EXAM RULE : Do NOT start high-dose beta-blockers acutely on the day of surgery in naive patients (POISE trial: increases severe bradycardia, stroke, and all-cause mortality). Titrate ≥ 2 – 4 \ge 2\text{--}4 ≥ 2 – 4 weeks prior if indicated.

Statins (HMG-CoA Reductase Inhibitors) CONTINUE without interruption Pleiotropic anti-inflammatory and plaque-stabilizing properties; reduces 30-day perioperative cardiac morbidity. Can even be initiated prior to vascular surgery.

ACE Inhibitors & ARBs (e.g., lisinopril, losartan) HOLD for 24 hours prior (omit morning of surgery dose) Inhibiting angiotensin II during general anesthesia induction triggers refractory vasoplegic hypotension unresponsive to standard alpha-agonists. Resume postoperatively once euvolemia is achieved.

SGLT2 Inhibitors (empagliflozin, dapagliflozin, canagliflozin) HOLD 3 to 4 days prior to elective surgery Surgical fasting and neuroendocrine stress induce relative insulinopenia and elevated glucagon, triggering life-threatening euglycemic Diabetic Ketoacidosis (euDKA) with normal serum glucose ( < 250 mg/dL <250\text{ mg/dL} < 250 mg/dL ). Hold empagliflozin, dapagliflozin, and canagliflozin for 3 days; hold ertugliflozin for 4 days.

Metformin HOLD on morning of surgery (24–48h if radiocontrast used) Perioperative hypovolemia or acute kidney injury combined with metformin accumulation elevates the risk of severe lactic acidosis .

Sulfonylureas (e.g., glipizide, glimepiride) HOLD on morning of surgery Fasting (NPO status) while taking secretagogues induces severe intraoperative hypoglycemia.

Basal Insulin (Glargine, Detemir, Degludec) REDUCE dose by 20% to 30% the night before/morning of surgery Prevents fasting hypoglycemia while maintaining basal suppression of lipolysis and ketogenesis. Prandial (rapid-acting) insulin is held while fasting. Perioperative blood glucose target: 140 to 180 mg/dL .

Aspirin (Low-Dose, 81 mg) CONTINUE in secondary prevention; hold 7 days only for closed-space surgery Continue for secondary prevention (prior stent, prior stroke) in most surgeries. Hold 7 days prior ONLY for closed-space surgeries where minor bleeding causes catastrophic outcomes: intracranial neurosurgery, posterior eye chamber surgery, and spinal canal surgery .

P2Y12 Inhibitors & Coronary Stents ELECTIVE SURGERY POSTPONEMENT MANDATE Noncardiac surgery MUST be delayed at least 30 days after Bare-Metal Stent (BMS) and at least 6 months (ideally 12 months) after Drug-Eluting Stent (DES) to prevent catastrophic in-stent thrombosis. If surgery cannot be delayed at 3–6 months: continue aspirin, hold clopidogrel for 5 days, ticagrelor for 3–5 days, or prasugrel for 7 days.

Direct Oral Anticoagulants (DOACs: Apixaban, Rivaroxaban) HOLD 24 to 72 hours based on bleeding risk and renal function Low bleeding risk: hold 24–48 hours (1–2 days). High bleeding risk: hold 48–72 hours (2–3 days). DO NOT BRIDGE DOACs with heparin : bridging dramatically increases major bleeding without reducing thromboembolism.

Warfarin HOLD 5 days prior (target INR ≤ 1.4 \le 1.4 ≤ 1.4 ) Heparin bridging (therapeutic LMWH) is indicated ONLY in high thromboembolic risk patients : mechanical mitral valve, older-generation mechanical aortic valve, acute VTE/stroke within 3 months, or CHA 2 DS 2 -VASc ≥ 7 – 8 \text{CHA}_2\text{DS}_2\text{-VASc} \ge 7\text{--}8 CHA 2 ​ DS 2 ​ -VASc ≥ 7 – 8 . Stop LMWH 24h prior.

Pre-Participation Physical Evaluation (PPE) in Athletics

The primary clinical objective of the Pre-Participation Physical Evaluation (PPE) is to identify life-threatening medical conditions—most notably those predisposing to sudden cardiac death (SCD) —and to ensure safe participation in sports. The PPE should ideally be scheduled at least 6 weeks prior to the sports season to provide sufficient lead time for diagnostic workup, rehabilitation, or subspecialist consultation of identified abnormalities.

The AHA 14-Element Cardiovascular Screening Checklist

The American Heart Association (AHA) recommends that every athletic PPE include a thorough 14-element cardiovascular screen comprising personal history, family history, and physical examination:

• Personal History (5 Elements)
• Exertional chest pain or chest discomfort
• Unexplained syncope, near-syncope, or severe exertional dizziness
• Excessive, unexplained exertional dyspnea or fatigue out of proportion to conditioning
• Prior detection of a heart murmur
• Prior diagnosis of systemic hypertension
• Family History (3 Elements)

Premature death (sudden, unexpected) before age 50 attributable to cardiovascular disease in ≥ 1 \ge 1 ≥ 1 relative

Disability from cardiovascular disease in a close relative under age 50

Specific knowledge of cardiac conditions in family members: hypertrophic cardiomyopathy (HCM) , dilated cardiomyopathy, long QT syndrome , Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy (ARVC), Marfan syndrome, or clinically important arrhythmias

Physical Examination (6 Elements)

Heart Murmur Auscultation : Auscultation in both supine and standing (or during Valsalva maneuver) to differentiate innocent flow murmurs from obstructive hypertrophic cardiomyopathy

Femoral Arterial Pulse Palpation : Bilateral palpation to detect radial-femoral pulse delay or diminished femoral amplitude indicative of coarctation of the aorta

Stigmata of Marfan Syndrome : Pectus excavatum or carinatum, arachnodactyly, high-arched palate, arm span exceeding height (ratio > 1.05 >1.05 > 1.05 ), joint hypermobility, severe myopia/lens subluxation

• Bilateral Seated Brachial Blood Pressure Measurement
• History of prior restriction from athletic participation
• History of prior cardiac testing ordered by a physician
• Dynamic Murmur Auscultation: HCM vs. Innocent Murmurs

Distinguishing hypertrophic cardiomyopathy (the leading cause of sudden cardiac death in young athletes in North America) from benign physiologic flow murmurs is an essential clinical skill: DYNAMIC AUSCULTATION IN ATHLETIC SCREENING

• ┌────────────────────────────────────────────────────────────────────────────────────────┐
• │ HYPERTROPHIC CARDIOMYOPATHY (HCM) │
• │ • Murmur: Harsh, crescendo-decrescendo systolic murmur at left lower sternal border │
• │ • Pathophysiology: Asymmetric septal hypertrophy causing dynamic LV outflow obstruction│
• │ • VALSALVA MANEUVER / STANDING (Decreased Venous Return / Decreased LV Volume): │
• │ ➔ Left ventricular cavity narrows, subaortic obstruction worsens │
• │ ➔ MURMUR INTENSITY INCREASES │
• │ • SQUATTING / PASSIVE LEG RAISE (Increased Venous Return / Increased LV Preload): │
• │ ➔ Expands left ventricular outflow tract, relieving obstruction │
• │ ➔ MURMUR INTENSITY DECREASES │
• └────────────────────────────────────────────────────────────────────────────────────────┘
• │
• Contrast With
• │
• ▼
• ┌────────────────────────────────────────────────────────────────────────────────────────┐
• │ INNOCENT / PHYSIOLOGIC FLOW MURMUR │
• │ • Murmur: Soft (Grade 1–2/6), early-to-midsystolic, vibratory/musical, LSB or pulmonic │
• │ • VALSALVA MANEUVER / STANDING (Decreased Preload): │
• │ ➔ Transvalvular flow volume diminishes │
• │ ➔ MURMUR INTENSITY DECREASES OR COMPLETELY DISAPPEARS │
• │ • SUPINE POSITIONING / SQUATTING: │
• │ ➔ Increased venous return enhances flow; MURMUR INCREASES │
• └────────────────────────────────────────────────────────────────────────────────────────┘

Aortic Stenosis Differentiation : Aortic stenosis produces a harsh systolic ejection murmur at the right upper sternal border that radiates to the carotids. Like innocent murmurs, aortic stenosis decreases in intensity with Valsalva (reduced transvalvular flow) and increases with squatting.

Athletic Clearance Categories

Upon completing the PPE, the physician assigns the athlete to one of four clearance categories:

Cleared without restriction for all sports.

Cleared with recommendations for further evaluation or treatment (e.g., cleared for track while beginning inhaled albuterol for exercise-induced bronchospasm).

Clearance deferred pending further evaluation (e.g., withholding clearance pending an echocardiogram to evaluate a murmur that intensifies with Valsalva).

Disqualified / Not cleared for specific or all sports (e.g., active acute myocarditis, severe symptomatic aortic stenosis, uncontrolled malignant arrhythmias).

Concussion Triage & Graduated Return-to-Play Protocol

A sport-related concussion is a traumatic brain injury induced by biomechanical forces. Clinical symptoms encompass somatic (headache, dizziness, nausea), cognitive (brain fog, amnesia, delayed processing), emotional (irritability, lability), and sleep disturbances.

The Golden Rule : Any athlete who exhibits signs, symptoms, or suspicion of a concussion following head or body trauma MUST BE REMOVED FROM PLAY IMMEDIATELY . Under no circumstances is an athlete allowed to return to play on the same day ("When in doubt, sit them out").

Evaluation : Utilize standardized tools such as the Sport Concussion Assessment Tool 6 (SCAT6) or Child SCAT6.

Graduated Return-to-Play (RTP) Protocol : Once the athlete has completed a brief 24- to 48-hour period of initial cognitive and physical rest and is symptom-free at rest, they may begin the structured 6-Stage Return-to-Play Protocol . Each stage requires a minimum of 24 hours . If concussion symptoms recur at any stage, activity must stop, the athlete rests for at least 24 hours until asymptomatic, and resumes at the previous asymptomatic stage : Stage 1: Symptom-Limited Activity

• Daily light walking, gentle cognitive activities; avoid vigorous exercise and screen overuse.

• │ (Minimum 24 hours asymptomatic)
• ▼
• Stage 2: Light Aerobic Exercise

• Stationary cycling or walking at slow-to-medium pace; heart rate <70% max; NO resistance training.

• │ (Minimum 24 hours asymptomatic)
• ▼
• Stage 3: Sport-Specific Exercise

• Running drills (soccer, basketball) or skating drills (hockey); NO head impact activities.

• │ (Minimum 24 hours asymptomatic)
• ▼
• Stage 4: Non-Contact Training Drills

• More complex training drills (passing, agility); initiation of progressive resistance training.

• │ (Minimum 24 hours asymptomatic)
• ▼
• Stage 5: Full-Contact Practice

• MANDATORY MEDICAL CLEARANCE REQUIRED; normal training activities and contact drills.

• │ (Minimum 24 hours asymptomatic)
• ▼
• Stage 6: Return to Competition

• Normal game play and full unrestricted athletic competition.

Loading diagram... ACC/AHA Perioperative Cardiac Evaluation & Athletic PPE Murmur Triage